Immupharma (IMM) RNS Announcements

Add to Alert list
Date Time Source Announcement
21 Oct 2014 07:00 AM
RNS
Additional Listing - Conditional Placing
20 Oct 2014 07:00 AM
RNS
ImmuPharma awarded EUR400,000 Grant
30 Sep 2014 07:05 AM
RNS
Half Yearly Report
30 Sep 2014 07:00 AM
RNS
LupuzorT Gears Up To Start Pivotal Phase III trial
27 Jun 2014 01:11 PM
RNS
Result of AGM
27 Jun 2014 07:00 AM
RNS
Access to pioneering research in Bordeaux France
16 Jun 2014 07:00 AM
RNS
NEW NUCANT PATENTS
23 May 2014 07:00 AM
RNS
Annual Financial Report
21 May 2014 07:00 AM
RNS
Preliminary Results
06 May 2014 12:47 PM
RNS
Dr. Sylviane Muller - Presentation Abstract
23 Apr 2014 07:00 AM
RNS
Dr. S Muller, founder of Lupuzor presentation.
11 Apr 2014 07:00 AM
RNS
ImmuPharma Sponsors the 2014 European Lupus Confer
14 Oct 2013 07:00 AM
RNS
Additional Listing
27 Sep 2013 07:00 AM
RNS
Half Yearly Report
13 Aug 2013 07:00 AM
RNS
UPDATE CANCER PROGRAMME IPP-204106
31 Jul 2013 07:00 AM
RNS
FDA GRANTS IMMUPHARMA AMENDED SPA
08 Jul 2013 08:00 AM
RNS
IMMUPHARMA APPOINTS WORLDWIDE KEY OPINION LEADERS
05 Jun 2013 07:00 AM
RNS
Holding(s) in Company
23 May 2013 12:29 PM
RNS
Result of AGM
21 May 2013 07:00 AM
RNS
?50M Financing Facility - Darwin Strategic
22 Apr 2013 07:00 AM
RNS
Posting of Annual Report and AGM Notice
09 Apr 2013 07:00 AM
RNS
Preliminary Results
28 Feb 2013 07:01 AM
RNS
ImmuPharma Commences Trading on Stuttgart Exchange
28 Jan 2013 04:03 PM
RNS
Director/PDMR Shareholding - Replacement
28 Jan 2013 01:18 PM
RNS
Director/PDMR Shareholding
28 Jan 2013 09:33 AM
RNS
CNRS Confirms Lupuzor's (TM) Effectiveness
15 Nov 2012 07:30 AM
RNS
Lupuzor Presentation
05 Nov 2012 07:00 AM
RNS
Lupuzor Presentation
03 Oct 2012 07:00 AM
RNS
Notification of Major Interest in Shares
26 Sep 2012 07:01 AM
RNS
First Cancer Patients in New Trial Begin Dosing
26 Sep 2012 07:00 AM
RNS
Interim Results
20 Sep 2012 07:00 AM
RNS
Notification of Interim Results
07 Sep 2012 11:12 AM
RNS
Rodman and Renshaw Conference
17 Aug 2012 09:11 AM
RNS
Notification of Major Interest in Shares
11 Jul 2012 07:00 AM
RNS
Voted Best Medical Research & Development Company
09 Jul 2012 07:00 AM
RNS
New Corporate Website
03 Jul 2012 07:00 AM
RNS
Appointment of Joint Broker
23 May 2012 12:20 PM
RNS
Annual General Meeting: 2012
17 Apr 2012 07:00 AM
RNS
Posting of Annual Report and AGM Notice
27 Mar 2012 07:00 AM
RNS
Preliminary Results
20 Mar 2012 07:00 AM
RNS
Notification of Full Year Results
29 Feb 2012 07:00 AM
RNS
Appoints Head of Investor Relations
24 Jan 2012 12:44 PM
RNS
Director's Dealings
08 Nov 2011 11:43 AM
RNS
Notification of Major Interest in Shares
03 Nov 2011 07:00 AM
RNS
LupuzorT granted approval to start phase III
01 Nov 2011 10:23 AM
RNS
Notification of Major Interest in Shares
01 Nov 2011 10:18 AM
RNS
Notification of Major Interest in Shares
21 Oct 2011 07:00 AM
RNS
ImmuPharma regains Lupuzor rights
30 Sep 2011 07:00 AM
RNS
INTERIM RESULTS ANNOUNCEMENT
23 Sep 2011 09:34 AM
RNS
Notification of Interim Results

ImmuPharma is a pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France. 

ImmuPharma listed on AIM under the ticker IMM. 

IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.

IMM share price listed in London at 1,190p in 2000. 

UK 100